Avidity Biosciences (RNA)

P/S ratio as of February 2026 (TTM): 540

According to Avidity Biosciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.97. At the end of 2025 the company had a P/S ratio of 300.

P/S ratio history for Avidity Biosciences from 2020 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	300	-8.91%
2024	330	339.83%
2023	75.0	-53.12%
2022	160	33.76%
2021	120	-15.29%
2020	141

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Pfizer PFE	2.45	-99.55%	🇺🇸 USA
GSK plc GSK	2.81	-99.48%	🇬🇧 UK
Sarepta Therapeutics SRPT	0.7866	-99.85%	🇺🇸 USA
PTC Therapeutics PTCT	3.18	-99.41%	🇺🇸 USA
Fate Therapeutics FATE	24.4	-95.48%	🇺🇸 USA
Acorda Therapeutics ACOR	0.0071	-100.00%	🇺🇸 USA
Acceleron Pharma XLRN	N/A	N/A	🇺🇸 USA
Catalyst Pharmaceuticals CPRX	5.13	-99.05%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Avidity Biosciences (RNA)

P/S ratio as of February 2026 (TTM): 540